Zydus Lifesciences rises on launching ANVIMO for transplant patients
Zydus Lifesciences is currently trading at Rs. 880.05, up by 8.25 points or 0.95% from its previous closing of Rs. 871.80 on the BSE.
The scrip opened at Rs. 879.80 and has touched a high and low of Rs. 884.75 and Rs. 871.65 respectively. So far 25703 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 859.15 on 04-Mar-2025.
Last one week high and low of the scrip stood at Rs. 899.75 and Rs. 859.15 respectively. The current market cap of the company is Rs. 88568.72 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.18% and 6.84% respectively.
Zydus Lifesciences has launched ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will be available in dosages of 240 mg and 480 mg. ANVIMO provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes.
Transplantation is a life-saving but financially burdensome procedure in India. The high cost of post-transplant care, particularly CMV prophylaxis, adds to the burden. Until now, innovator Letermovir 240 mg was imported at Rs 5 lakh + per month, severely limiting access. With the launch of ANVIMO, the company has significantly reduced the cost by 91% of the innovator price, making treatment of CMV prophylaxis significantly more affordable for Indian patients. ANVIMO has established bioequivalence with the reference drug, ensuring quality at a fraction of the cost.
With ANVIMO, the company is transforming CMV prophylaxis in India, ensuring that more transplant patients receive timely, effective, and affordable care, ultimately improving survival rates and quality of life.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
